Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer
S. L. DeAngelo, L. Zhao, S. Dziechciarz, M. Shin, S. Solanki, A. Balia, M. O. El-Derany, C. Castillo, Y. Qin, N. K. Das, H. N. Bell, J. A. Paulo, Y. Zhang, N. J. Rossiter, E. C. McCulla, , Y. M. Shah
This study recharacterizes RSL3 as a broad selenoprotein inhibitor, showing its potential as a therapeutic target for colorectal cancer by inducing ferroptosis.
bioRxiv · Mar 29, 2024 · PreprintCancer Biology